LOGIQ E9

Device GE HEALTHCARE
Total Payments
$91,733
Transactions
3
Doctors
0
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2021 $59,839 1 0
2017 $31,894 2 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $91,733 3 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
PLATELET-RICH PLASMA THERAPY FOR PATELLAR TENDINOPATHY: A RANDOMIZED CONTROLLED TRIAL CORRELATING CLINICAL BIOMECHANICAL AND NOVEL IMAGING BIOMARKERS GE Healthcare $59,839 0
ULTRASOUND SYSTEM PERFORMANCE EVALUATION GE HEALTHCARE $16,894 0
EVALUATION OF CLINICAL BENEFITS OF BFLOW WITH THE LOGIQ E9 ULTRASOUND SYSTEM GE HEALTHCARE $15,000 0

Top Doctors Receiving Payments for LOGIQ E9

Doctor Specialty Location Total Records
Unknown Seattle, WA $91,733 3

About LOGIQ E9

LOGIQ E9 is a device associated with $91,733 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.

Payment data is available from 2017 to 2021. In 2021, $59,839 was paid across 1 transactions to 0 doctors.

The most common payment nature for LOGIQ E9 is "Unspecified" ($91,733, 100.0% of total).

LOGIQ E9 is associated with 3 research studies, including "PLATELET-RICH PLASMA THERAPY FOR PATELLAR TENDINOPATHY: A RANDOMIZED CONTROLLED TRIAL CORRELATING CLINICAL BIOMECHANICAL AND NOVEL IMAGING BIOMARKERS" ($59,839).